Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy

Clinical Drug Investigation

Volumn 24, Issue 8, 2004, Pages 479-486

  Gilissen, L P L ^a   Derijks, L J J ^b   Bos, L P ^c   Bus, P J ^d   Hooymans, P M ^c   Engels, L G J B ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MÁXIMA MEDICAL CENTER   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

^d LAURENTIUS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ACETYLSALICYLIC ACID DERIVATIVE; AZATHIOPRINE; DRUG METABOLITE; METHYLMERCAPTOPURINE; TIOGUANINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DETERMINATION; DRUG ERYTHROCYTE LEVEL; DRUG MONITORING; DRUG TOLERABILITY; ENTERITIS; FEMALE; HEMATOLOGICAL PARAMETERS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LABORATORY TEST; LIVER TOXICITY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PANCREAS DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCORING SYSTEM; STEADY STATE; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 4344587708     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200424080-00006     Document Type: Article

References (37)

1. Lancaster DL, Lennard L, Rowland K, et al. Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: a comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 1998; 102: 439-43
2. Bergan S, Rugstad HE, Bentdal O, et al. Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment. Ther Drug Monit 1994; 16: 13-20
3. Suarez-Almazor M, Spooner C, Belseck E. Azathioprine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001461
4. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med 1995; 123 (2): 132-42
5. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine and methotrexate. Am J Gastroenterol 1996; 91 (3): 423-33
6. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111 (8): 641-9
7. Adler DJ, Korelitz BI. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990; 85 (6): 717-22
8. Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (or how pharmacogenomics can make old drugs brand new). Inflamm Bowel Dis 2001; 7(3): 190-1
9. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43 (4): 329-39
10. Hanauer SB, Meyers SM. Management of Crohn's disease in adults. Am J Gastroenterol 1997; 92 (4): 559-66
11. Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37: 674-8
12. Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine: a long-term randomised double-blind study. N Engl J Med 1980; 302: 981-7
13. Sandborn WJ. Rational dosing of azathioprine and 6-mercaptopurine. Gut 2001; 48: 591-2
14. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13
15. Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48 (5): 642-6
16. Cuffari C, Theoret Y, Latour S, et al. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6
17. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70
18. Gupta P, Gokhale R, Kirschner B. 6-Mercaptopurine (6MP) metabolite levels in children with IBD. J Pediatr Gastroenterol Nutr 2001; 33 (4): 450-4
19. Cuffari C, Hunt S, Bayless T. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 1009-14
20. Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7 (3): 181-9
21. Derijks LJJ, De Jong DJ, Gilissen LPL, et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 2003; 15 (1): 63-7
22. Dubinsky MC, Feldman EJ, Abreu MT, et al. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol 2003; 98 (5): 1058-63
23. Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111 (8): 133-45
24. Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 143-6
25. Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 188: 1025-30
26. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115(4): 813-21
27. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34 (8): 1081-5
28. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125: 298-303
29. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report on a therapeutic trial. BMJ 1955; 4947: 1041-8
30. Lennard L, Singleton HJ. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-mercaptopurine metabolites in a single sample. J Chromatogr 1992; 583 (1): 83-90
31. Derijks LJJ, Gilissen LPL, Engels, LGJ, et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 2004; 26: 311-8
32. Pettersson B, Almer S, Albertioni F, et al. Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate [abstract]. Ther Drug Monit 2002; 24: 351-8
33. Reuther LO, Vainer B, Sonne J, et al. Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders: the impact of TPMT genotyping in predicting toxicity. Eur J Clin Pharmacol 2003; 59 (11): 797-801
34. Gearry RB, Barclay ML, Burt MJ, et al. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 118: 395-400
35. Curvers WL, Derijks LJJ, Stokkers P, et al. No predictive value of TPMT genotyping for leukopenia or hepatotoxicity during azathioprine therapy in inflammatory bowel disease [abstract]. Eur J Gastroenterol Hepatol 2003; 15(12): A29
36. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995; 72: 1004-6
37. Webster S, Sanders DS, Lennard L, et al. Azathioprine metabolites in inflammatory bowel disease and incidence of noncompliance [abstract]. Gut 2002; 50 Suppl. II: A71